Open Access4CPS-103 Second-generation tyrosin kinase inhibitors in front-line therapy. comparing responses
Author(s) -
CM Valencia Soto,
R López-Sepúlveda,
F Artime-Rodríguez-Hermida,
Sabrina Herrera,
MV Villacañas-Palomares,
P Nieto Gómez,
S Cortes-de Miguel
Publication year - 2018
Publication title -
section 4: clinical pharmacy services
Language(s) - Uncategorized
Resource type - Conference proceedings
DOI - 10.1136/ejhpharm-2018-eahpconf.194
Subject(s) - nilotinib , dasatinib , medicine , imatinib , observational study , tyrosine kinase inhibitor , imatinib mesylate , chronic myeloid leukaemia , regimen , first line , oncology , myeloid leukemia , cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom